Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06212999 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa
A Phase 3 study of Hidradenitis Suppurativa (HS), sponsored by Incyte Corporation.
- Active
- Registry status
- Phase 3
- Development phase
- 617
- Enrollment target
- 20
- Study locations
NCT06212999: Active Phase 3 study of Hidradenitis Suppurativa (HS), sponsored by Incyte Corporation.
NCT06212999 is a Phase 3 study of Hidradenitis Suppurativa (HS) that is active but no longer recruiting, run by Incyte Corporation. The registered enrollment target is 617 participants, above the 129-participant average among 12 other Hidradenitis Suppurativa (HS) trials with a reported enrollment target (378% higher). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06212999, a Phase 3 study of Hidradenitis Suppurativa (HS), is active but no longer recruiting, sponsored by Incyte Corporation.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 617 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate long-term safety and efficacy of povorcitinib in participants with moderate to severe hidradenitis suppurativa who completed the 54 weeks of study treatment within the originating parent Phase 3 studies (INCB 54707-301 \[NCT05620823\] or INCB 54707-302 \[NCT05620836\]).
Primary Outcome
TEAE is defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it is considered drug-related. An AE can therefore be any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug.
Conditions Studied
Interventions
- DRUG Povorcitinib
Study Locations (20)
Florida
- Investigative Site US309 - Clearwater
- Investigative Site US317 - Hialeah
- Investigative Site US306 - Hollywood
- Investigative Site US320 - Hollywood
- Investigative Site US316 - Maitland
- Investigative Site US227 - Margate
- Investigative Site US204 - Miami
- Investigative Site US236 - Miami
- Investigative Site US321 - North Miami Beach
- Investigative Site US200 - Ocala
- Investigative Site US228 - Tampa
- Investigative Site US201 - Tampa
California
- Investigative Site US315 - Laguna Niguel
- Investigative Site US223 - Los Angeles
- Investigative Site US222 - Oakland
- Investigative Site US226 - San Diego
Arizona
- Investigative Site US303 - Phoenix
- Investigative Site US240 - Scottsdale
Arkansas
- Investigative Site US307 - Fort Smith
- Investigative Site US214 - Rogers
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 617 participants |
| Start Date | 2024-01-30 |
| Est. Completion | 2026-12-26 |
| Phase | Phase 3 |
What the registry record for NCT06212999 still lists
NCT06212999 is an interventional study that assigns participants to a tested intervention. The registered 617 participants enrollment target is mid-sized for trials with a published cap, above the 129-participant average among 12 other Hidradenitis Suppurativa (HS) trials with a reported enrollment target (378% higher).
The record links to 1 condition, with Hidradenitis Suppurativa (HS) appearing as the primary indexed condition, and to 1 intervention - of which Povorcitinib is the first listed.
NCT06212999 names 20 study sites across 4 states, led by Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT06212999 about?
NCT06212999 is a clinical study titled "A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa". The purpose of this study is to evaluate long-term safety and efficacy of povorcitinib in participants with moderate to severe hidradenitis suppurativa who completed the 54 weeks of study treatment within the originating parent Phase 3 studies (INCB 54707-301 \[NCT05620823\] or INCB 54707-302 \[NCT0...
What is the current status of trial NCT06212999?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 617 participants. The study started on 2024-01-30. Estimated completion is 2026-12-26.
What conditions does trial NCT06212999 study?
This clinical trial studies the following conditions: Hidradenitis Suppurativa (HS).
What interventions are being tested in trial NCT06212999?
The interventions under investigation include: Povorcitinib (DRUG).
Who is sponsoring clinical trial NCT06212999?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06212999 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hidradenitis Suppurativa (HS)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06212999's enrollment target sits among peer trials
617 1st of 12 higher than 12 of 12 other Hidradenitis Suppurativa (HS) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hidradenitis Suppurativa (HS) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
RECRUITING · Phase 3
-
Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense
RECRUITING · Phase 2
-
A Study to Assess NAV-240 in Adult Participants With Hidradenitis Suppurativa
RECRUITING · Phase 2
-
The Safety and Efficacy of Roflumilast Foam in HS
RECRUITING · Phase 2
-
Participants with Mild to Moderate Hidradenitis Suppurativa Will Receive EVO101 a Topical Cream 0.1%
RECRUITING · Early Phase 1
-
1726-nm Laser for Acne Inversa (Hidradenitis Suppurativa)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02610179 · 617 participants · NA
Strawberry Candy Twists as an Alternative Screen for Gestational Diabetes: A Prospective Trial
- NCT05672927 · 618 participants · Phase 4
Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old)
- NCT06220721 · 618 participants · NA
Reducing the Risk of Chronic Hypertension and Improving Vascular Function Following Preeclampsia
- NCT04813185 · 616 participants · NA
Preventing Retaliatory Gun Violence in Violently Injured Adults
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI